How I treat advanced Hodgkin lymphoma - a global view.
作者信息
Hokland Peter, Shah Mansi, David Kevin, Evens Andrew, Auer Rebecca, Ledieu Rifca, Kreissl Stefanie, Bröckelmann Paul J, Borchmann Peter, Korula Anu, Mathews Vikram, Owattanapanich Weerapat, Trotman Judith
机构信息
Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
出版信息
Br J Haematol. 2020 Sep;190(6):837-850. doi: 10.1111/bjh.16587. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
How I treat advanced Hodgkin lymphoma - a global view.我如何治疗晚期霍奇金淋巴瘤——全球视角
Br J Haematol. 2020 Sep;190(6):837-850. doi: 10.1111/bjh.16587. Epub 2020 Jun 19.
2
[Therapy of Hodgkin lymphoma: chances of remission are good, treatment tolerance needs improvement].[霍奇金淋巴瘤的治疗：缓解机会良好，治疗耐受性有待提高]
MMW Fortschr Med. 2011 Oct 13;153(41):17. doi: 10.1007/BF03368883.
3
Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010.霍奇金淋巴瘤中期正电子发射断层扫描卫星研讨会报告：第八届国际霍奇金淋巴瘤研讨会，科隆，2010年10月23日。
Leuk Lymphoma. 2011 Apr;52(4):583-6. doi: 10.3109/10428194.2010.551162.
4
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.仅通过化疗使霍奇金淋巴瘤患者达到氟脱氧葡萄糖正电子发射断层扫描（FDG PET）阴性状态后省略放疗：一项随机研究的警示
Leuk Lymphoma. 2007 Sep;48(9):1667-9. doi: 10.1080/10428190701606875.
5
Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma.霍奇金淋巴瘤治疗后，继发于良性组织细胞增殖的持续性正电子发射断层扫描阳性。
Leuk Lymphoma. 2007 Mar;48(3):616-8. doi: 10.1080/10428190601140058.
6
[18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.[18F]氟脱氧葡萄糖正电子发射断层扫描在淋巴瘤管理中的应用
Clin Lymphoma Myeloma. 2008 Oct;8(5):273-6. doi: 10.3816/CLM.2008.n.037.
7
[FDG-PET in Hodgkin lymphoma].[氟代脱氧葡萄糖正电子发射断层扫描在霍奇金淋巴瘤中的应用]
Nuklearmedizin. 2008;47(6):235-8; quiz N75-6. doi: 10.3413/nukmed-0216.
8
Combination chemoradiotherapy in early Hodgkin lymphoma.早期霍奇金淋巴瘤的联合化放疗。
Hematol Oncol Clin North Am. 2014 Feb;28(1):33-47. doi: 10.1016/j.hoc.2013.10.010.
9
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.PET-2 引导的强化 BEACOPP 方案治疗晚期结节性淋巴细胞为主型霍奇金淋巴瘤：德国霍奇金研究组 HD18 随机研究的亚组分析
Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3.
10
Cervical thymic hyperplasia after chemotherapy in an adult patient with Hodgkin lymphoma: a potential cause of false-positivity on [18F]FDG PET/CT scanning.成年霍奇金淋巴瘤患者化疗后发生的颈部胸腺增生：[18F]FDG PET/CT扫描假阳性的一个潜在原因
Br J Haematol. 2008 Mar;140(5):477. doi: 10.1111/j.1365-2141.2007.06901.x. Epub 2007 Dec 10.
引用本文的文献
1
[Clinical characteristics and survival analysis of pediatric Hodgkin lymphoma: a multicenter study].[儿童霍奇金淋巴瘤的临床特征与生存分析：一项多中心研究]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jun 15;27(6):668-674. doi: 10.7499/j.issn.1008-8830.2412144.
2
Harnessing multi-source data for individualized care in Hodgkin Lymphoma.利用多源数据为霍奇金淋巴瘤患者提供个体化护理。
Blood Rev. 2024 May;65:101170. doi: 10.1016/j.blre.2024.101170. Epub 2024 Jan 14.
3
Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.霍奇金淋巴瘤的连续护理：现代疗法对急性后期发病率和死亡率的影响。
J Clin Oncol. 2020 Dec 10;38(35):4131-4134. doi: 10.1200/JCO.20.02668. Epub 2020 Oct 8.
本文引用的文献
1
Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.晚期霍奇金淋巴瘤患者一线治疗方案的成本效益：一项建模研究。
Lancet Haematol. 2020 Feb;7(2):e146-e156. doi: 10.1016/S2352-3026(19)30218-2. Epub 2020 Jan 13.
2
Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting.在资源有限的情况下，成像方式对霍奇金淋巴瘤临床结局的影响。
Br J Haematol. 2020 Mar;188(6):930-934. doi: 10.1111/bjh.16289. Epub 2019 Dec 7.
3
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.SWOG S0816 研究的 5 年随访结果：III/IV 期霍奇金淋巴瘤行 PET 修正治疗的局限性和价值。
Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.
4
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease.治疗新世纪的霍奇金淋巴瘤：复发和难治性疾病。
Hematol Oncol. 2019 Jun;37 Suppl 1:87-91. doi: 10.1002/hon.2589.
5
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.PET 指导下治疗新诊断的晚期霍奇金淋巴瘤（AHL2011）：一项随机、多中心、非劣效性、3 期研究。
Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.
6
Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.霍奇金淋巴瘤治疗的风险和获益：德国霍奇金研究组调查的结果。
Leuk Lymphoma. 2019 Jun;60(6):1389-1398. doi: 10.1080/10428194.2018.1540781. Epub 2018 Dec 3.
7
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.AETHERA 试验中 Brentuximab Vedotin 治疗高复发/进展风险霍奇金淋巴瘤的 5 年无进展生存数据。
Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28.
8
Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.难治性霍奇金淋巴瘤：明确自体移植的作用
Cancer J. 2018 Sep/Oct;24(5):244-248. doi: 10.1097/PPO.0000000000000330.
9
Transplant strategies in relapsed/refractory Hodgkin lymphoma.复发/难治性霍奇金淋巴瘤的移植策略。
Blood. 2018 Apr 12;131(15):1689-1697. doi: 10.1182/blood-2017-09-772673. Epub 2018 Mar 2.
10
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.ABVD 方案两周期后 PET/CT 阳性的晚期霍奇金淋巴瘤患者早期强化化疗：GITIL/FIL HD0607 试验的长期结果。
J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543. Epub 2018 Jan 23.
Zotero 插件